Effect of different exposures to desferrioxamine on neuroblastoma cell lines.

Abstract

Desferrioxamine (DFO) has shown anti-proliferative and cytotoxic effects on several tumor cells. DFO is used at present in the treatment of neuroblastoma in combination with chemotherapy (D-CECaT regimen: cyclophosphamide, etoposide, carboplatin, and thiotepa). We compared the effect of continuous or intermittent exposures to DFO on 3H-thymidine uptake, viability, and cell cycle of human neuroblastoma (NB) cell lines. Our results show that continuous exposures to DFO cause dose- and time-dependent cytotoxicity of NB cells, while intermittent exposures result in significant NB cell toxicity only when using high DFO concentrations. By 3H-thymidine uptake, a significant inhibition of proliferation was observed only in continuous exposures. In addition, a consistent arrest in G1 phase was detected only in cultures treated continuously with high DFO concentrations. Our data indicate that 3H-thymidine uptake, viability, and cell cycle changes are proportional to the extent of exposure and concentration of DFO, suggesting that in vivo DFO continuous infusion may improve anti-neuroblastoma activity.

• Authors: P Valle, F Timeus, M Piglione, P Rosso, L C di Montezemolo, N Crescenzio, D Marranca, U Ramenghi
• Journal: Pediatric hematology and oncology (Pediatr Hematol Oncol) 1995 Sep-Oct Vol. 12 Issue 5 Pg. 439-46 ISSN: 0888-0018 [Print] England
• PMID: 8519628 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Deferoxamine
• Thymidine

Topics

• Antineoplastic Agents (pharmacology)
• Cell Cycle (drug effects)
• Cell Survival (drug effects)
• Deferoxamine (administration & dosage, pharmacology)
• Dose-Response Relationship, Drug
• Humans
• Neuroblastoma (pathology)
• Thymidine (metabolism)
• Tumor Cells, Cultured